Reunion Neuroscience, Inc.

November is Lung Cancer Awareness Month. We're honoring those affected and exploring new ways to support emotional health. Our REKINDLE trial studies RE104, a psychedelic-inspired therapy for Adjustment Disorder in cancer patients. Learn more: rekindlestudies.com #LungCancerAwarenessMonth

It’s a time to honor the strength of those impacted by breast cancer, and to recognize that healing goes beyond the physical. Our REKINDLE Ph 2 trial is exploring RE104, a psychedelic-inspired therapeutic, for AjD in patients with cancer & other serious illnesses. REKINDLE study: rekindlestudies.com

Today, we announced the dosing of the first patient in REKINDLE, our Ph 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other serious medical conditions.

Read the release: bit.ly/3KsOU6M

#psychedelictherapeutics #adjustmentdisorder

Are you attending the 8th Annual Maternal Mental Health Symposium? Camille Hoffman, MD, MSCS, lead investigator in our RECONNECT trial, will be presenting clinical insights on RE104, our novel psychedelic therapy for #postpartumdepression. Registration is FREE for this virtual event!

Today, we announced the final closing of our Series A Financing and shared plans to advance RE104 into clinic development for the treatment of Generalized Anxiety Disorder (GAD).

Read the full release for more specifics: bit.ly/48icPPS

#mentalhealth #clinicaldevelopment #innovation

Today, we announced positive topline results in our RECONNECT Ph 2 trial, representing a meaningful breakthrough and new hope for women with postpartum depression (#PPD). Explore the full data and outcomes in the news release: bit.ly/45Ty3lw
#postpartumdepression #maternalmentalhealth

Our manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” has published in Journal of Clinical Psychopharmacology. See release news here: bit.ly/4lJJnq2

The public version of the Women's Health article is here! You don't want to miss out on Lawrence Leeman, MD discussing our leading single-dose psychedelic therapy, RE104, currently being evaluated in our RECONNECT Ph 2 clinical trial for women battling #ppd. Check it out here: bit.ly/3IcmkFA

Thank you to Maria Shriver and the NBCNews Today Show for the opportunity to bring awareness to our new potential therapy for mothers battling #PPD. We appreciate Melissa Lavasani & Keith Heinzerling for their personal & professional contributions to this cause. View here: bit.ly/3Gc5CFB

🚨Attention🚨 Be sure to tune in to the Today Show on @NBCNews tomorrow (June 25) at 8am ET to see our interview with @Maria Shriver on #maternalmentalhealth and #postpartumdepression. See you there!

Are you attending Psychedelic Science 2025? Our SVP of Clinical Development & Regulatory Affairs, Beatrix Taylor, MSc, RAC, will be presenting an update on our RECONNECT Ph 2 study in #PPD, and the study design for our upcoming REKINDLE Ph 2 trial in #adjustment disorder. #PS2025 #PsychSci

Are you attending the ASCP Annual Meeting ? Our CMO, Mark Pollack, MD, will present results from our Phase 1 trial of RE104, supporting the advancement of RE104 in our Phase 2 RECONNECT and REKINDLE trials for innovative treatment in PPD and adjustment disorder. #ASCP2025 #mentalhealth

Big news! We have completed enrollment and dosed our last patient in our RECONNECT Phase 2 clinical trial for the treatment of #pppd, with topline results expected in Q3 2025. #maternalmentalhealth #ppd
Read more here: bit.ly/4jt37fP

We are featured in @womens-healthmag.bsky.social discussing our leading single-dose #psychedelic therapy, RE104, being evaluated in our RECONNECT Ph 2 clinical trial to help provide women suffering from #ppd with a potential new rapid-acting treatment solution. Full article: lnkd.in/eJb36zCn

Join us at the 5th Annual Psychedelic Therapeutics & Drug Development Conference May 19-20 in San Diego! Our COO, Mark Theeuwes, will be presenting our clinical plan for the progress of our #PPD RECONNECT Ph 2 trial, and our upcoming REKINDLE Phase 2 trial for the treatment of #adjustmentdisorder.

Kicking off Maternal Mental Health Awareness Week, a vital reminder that too many women suffer in silence with #PPD. We are committed to changing this for women with our leading #psychedelic treatment, RE104. For more info on our RECONNECT study, visit ppdreconnectstudy.com. #MaternalMentalHealth

In a conversation with Andrea Dukakis from Colorado Public Radio, Dr. Camille Hoffman discusses postpartum depression and the use of psilocybin and shared details about our RECONNECT trial. If you'd like to listen, the discussion begins at 33:21 - bit.ly/3GAXQ7S

Brian Barnett, MD, from the Cleveland Clinic spoke with Cleveland.com about the use of synthetic psychedelics for women suffering from PPD, and how our RE104 treatment is currently being evaluated at the Clinic's trial site. Learn more about our RECONNECT trial & enrollment: bit.ly/42vwIQn

Psychedelics for postpartum depression with Melissa Lavasani | We Are More Than Moms

In the “We Are More Than Moms: Unfiltered” podcast, @melissalavasani.bsky.social, a mother of two, shares her powerful journey with postpartum depression and how psychedelics became a turning point in her healing. Thank you for sharing your story, Melissa. Listen to the episode here: bit.ly/3EBa6EU

Still relevant. Still important. We’re resurfacing this Patient Safety & Quality Healthcare article by Dr. Sheryl Kingsberg on new progress in treating postpartum depression to keep the conversation going and highlight our current RECONNECT study. Read it here: bit.ly/3YWUfaY

In case you missed it, Jeffrey Newport, MD, chatted with Trevor Scott on CBS Austin's 'We Are Austin' (KEYE-TV) about our RECONNECT study a few weeks ago. Here is a behind the scene image, and be sure to watch the great (and informative) interview here: bit.ly/3QYCsvc

In Hatch Magazine, Melissa Lavasani shares why traditional treatments often fall short for moms facing #PPD, and how our rapid-acting #psychedelic therapy in the RECONNECT study (ppdreconnectstudy.com) has the potential to change the future of #maternalmentalhealth.
Read here: bit.ly/4lrYowY

Empowered Patient Podcast: Developing Psychedelic Therapy for Rapid Improvement of Postpartum Depression with Greg Mayes Reunion Neuroscience Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affe...

If you haven't listened to it yet, check out our President & CEO, Greg Mayes, on the Empowered Patient Podcast with Karen Jagoda. He dives into Reunion’s work developing #psychedelic therapy for rapid #postpartumdepression. Listen now: bit.ly/3BDKHJb

#maternalmentalhealth #RECONNECTstudy #PPD

At the ADAA 2025 Conference April 3-5, we presented our study design for the REKINDLE Ph 2 clinical trial evaluating our leading #psychedelic candidate, RE104, for the treatment of Adjustment Disorder (AjD) in patients with cancer & other medical illnesses. See our release news here: bit.ly/4cqdrDp

Our President and CEO, Greg Mayes, spoke with Pharma's Almanac about our novel single-dose #psychedelic therapy, RE104, for women battling PPD, and our RECONNECT study (ppdreconnectstudy.com). Check out the amazing article interview here: bit.ly/4ldnkbt

#postpartumdepression #maternalmentalhealth

Watch Melissa Lavasani on Cherished Mom’s Finding Hope: Stories of Resilience and the Future of PPD Care webinar share her powerful story of how she overcame #PPD with the use # #psilocybin, and our RECONNECT study. Get more info at: ppdreconnectstudy.com
View here: bit.ly/3RfSIrX

Laura Keller shared her inspiring journey during Cherished Mom’s Finding Hope: Stories of Resilience & the Future of PPD Care event on overcoming #PPD, and how hopeful she is for our #psychedelic treatment, RE104. Get more info at: ppdreconnectstudy.com.
Watch webinar here: bit.ly/3RfSIrX

Our Principal Investigator at the Cleveland Clinic, Brian Barnett, MD spoke with NBC affiliate WKYC about our lead candidate, RE104, a novel single-dose #psychedelic therapy being evaluated in our RECONNECT Study (ppdreconnectstudy.com) for women with #PPD.
Watch here: bit.ly/4hjBHYx

Jeffrey Newport, MD was a guest on We Are Austin discussing how #PPD affects many women worldwide, and that there is new hope in innovative treatment with the use of our single-dose #psychedlic therapy in our RECONNECT Ph 2 study (ppdreconnectstudy.com). Check out the segment: bit.ly/3QYCsvc

Our President and CEO, Greg Mayes, was featured in DoubleBlind discussing our single-dose #psychedelic therapy, RE104, as a new innovative treatment option being evaluated for mothers suffering from #PPD in our RECONNECT Ph 2 study (ppdreconnectstudy.com). Read more here: bit.ly/43BARTE